Lasea und Stillen möglich?

Liebe Kaline,

zu Lasea gibt es - wie bei vielen pflanzlichen Mitteln - keine hinreichende Datenlage, um die Vereinbarkeit mit dem Stillen wirklich beurteilen zu können.

Die Informationen bei Toxnet Toxicology Data Network (einer Datenbank der National Library of Medicine in den USA, leider nur auf Englisch) beziehen sich überwiegend auf einen speziellen Bestandteil des Lavendel, das Eukalyptol, so dass diese Erfahrungen wohl nicht als ausreichend für eine Beurteilung des von dir genannten Präparates anzusehen sind.

"SUMMARY OF USE DURING LACTATION:
Lavender (Lavendula angustifolia) flowers, leaves and oil contain linaloyl acetate, linalool, perillyl alcohol, 1,8 cineole (eucalyptol), and at least 100 other known compounds. Lavender has no specific lactation-related uses. Lavender preparations have traditionally been used for anxiety and other neurologic conditions, infections, pain and a variety of other conditions, often as aromatherapy. None of these uses have good scientific evidence to support their use. Lavender is "generally recognized as safe" (GRAS) as a food by the US Food and Drug Administration. In general, lavender is well tolerated, but no data exist on the excretion of any components of lavender into breastmilk or on the safety and efficacy of lavender in nursing mothers or infants. Lavender oil may have some minor estrogenic and antiandrogenic activity, so topical application around the breast should be avoided. Dietary supplements do not require extensive pre-marketing approval from the US Food and Drug Administration. Manufacturers are responsible to ensure the safety, but do not need to prove the safety and effectiveness of dietary supplements before they are marketed. Dietary supplements may contain multiple ingredients, and differences are often found between labeled and actual ingredients or their amounts. A manufacturer may contract with an independent organization to verify the quality of a product or its ingredients, but that does not certify the safety or effectiveness of a product. Because of the above issues, clinical testing results on one product may not be applicable to other products. More detailed Information about dietary supplements is available elsewhere on the LactMed Web site.

DRUG LEVELS:
Maternal Levels. Twelve nursing mothers who were19 weeks to 19 months postpartum ingested 100 mg of 1,8 cineole (eucalyptol) in the form of delayed-release capsules (Soledum-Klosterfrau Vertriebs GmbH, Germany) that release the drug in the intestine. Then they pumped 1 to 4 milk samples at the time they perceived the smell of eucalyptus on their breath which had been previously shown to be approximately concurrent. A total of 21 milk samples were obtained. Odor was rated by a panel of 3 to 5 experts as either smelling like eucalyptus or not. Fourteen of the samples had a distinct eucalyptus-like odor. Chemical analysis of the positive odor tests found 1,8-cineole in concentrations from 70 to about 2090 mcg/kg of milk, most in the range of 100 to 500 mcg/kg of milk. Samples with negative odor tests contained concentrations in the range of 0.98 to about 20.23 mcg/kg of milk. In one woman who donated 3 samples, the highest
concentration of 71 mcg/kg occurred at 1.5 hours after ingestion, with concentrations of 1 mcg/kg before ingestion and 15 mcg/kg at 9.5 hours after ingestion.[1] Eight women had their milk analyzed for 1,8-cineole metabolites. Ten metabolites and several enantiomers of these metabolites were detected.[2][3] Infant Levels. Relevant published information was not found as of the revision date.

EFFECTS IN BREASTFED INFANTS:
Nursing mothers who were participating in an experiment on the excretion
of 1,8-cineole (eucalyptol) in breastmilk took a 100 mg capsule of
1,8-cineole orally. Although instructed not to, 12 mothers breastfed their
infants during the experiment. Mothers reported that none of their infants
refused their milk or breastfed less than usual. Two mothers felt that
their infants were more agitated a few hours after breastfeeding. A third
mother reported that the infant stopped nursing from time to time and
"looked puzzled", but resumed nursing. Upon repeating the experiment 6
weeks later, the infant did not react in an unusual way during
breastfeeding.[1]
EFFECTS ON LACTATION AND BREASTMILK:
Gynecomastia occurred in 3 prepubertal boys who were using grooming
products containing lavender oil. The gynecomastia resolved after the
products were discontinued. In vitro testing found that lavender oil
possesses mild estrogenic and antiandrogenic activity.[4] The relevance of
these finding has been questioned,[5][6] but no further testing has been
reported to confirm or refute the findings as of the revision date.

REFERENCES:

1. Kirsch F, Beauchamp J, Buettner A. Time-dependent aroma changes in breast milk after oral intake of a pharmacological preparation containing 1,8-cineole. Clin Nutr. 2012;31:682-92.
2. Kirsch F, Buettner A. Characterisation of the metabolites of 1,8-cineole transferred into human milk: Concentrations and ratio of enantiomers. Metabolites. 2013;3:47-71.
3. Kirsch F, Horst K, Rohrig W et al. Tracing metabolite profiles in human milk: studies on the odorant 1,8-cineole transferred into breast milk after oral intake. Metabolomics. 2013;9:483-96.
4. Henley DV, Lipson N, Korach KS, Bloch CA. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med. 2007;356:479-85.
5. Kemper KJ, Romm AJ, Gardiner P. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med. 2007;356:2541-2; author reply 2543-4.
6. Kalyan S. Prepubertal gynecomastia linked to lavender and tea tree oils. N Engl J Med . 2007;356:2542; author reply 2543-4."

Zu Diltiazem zur äußerlichen Anwendung in der Stillzeit liegt mir ebenfalls keine Information vor. Laut "Roter Liste" gilt für die orale Anwendung "Substanz geht in die Milch über. Eine Schädigung des Säuglings ist bisher nicht bekannt geworden."

Laut "Arzneimittel in Schwangerschaftund Stillzeit" Spielmann, Schaefer et al. 8. Auflage 2011 S.649 gilt: "Während der Therapie mit Calcium-Antagonisten darf gestilltwerden. Je nach Indikation sind Diltiazem, Nicardipin, Nifedipin, Nitrendipinund Verapamil die Calcium-Antagonisten der Wahl in der Stillzeit. Auch ersteErgebnisse zu Amlodipin lassen kein Risiko erkennen. Einzelne Gaben andererCalcium-Antagonisten erfordern keine Einschränkung des Stillens, jedoch sollteein Umstellen der Therapie veranlasst werden."

In vielen Fällen ist es möglich, eine Beurteilung einer äußerlichen Anwendung aufgrund der Daten zur oralen Anwendung vorzunehmen. Das kann aber nur eine Ärztin oder ein Arzt.

Am besten besprichst Du mit deiner Ärztin oder deinem Arzt, was für dich in deiner Situation eine jeweils passende Behandlung ist. Sollte sie/er sich nicht sicher sein, kann sie/er bei der Beratungsstelle für Embryonaltoxikologie in Berlin für dich individuell nachfragen (www.embryotox.de oder Tel. 030 / 450-525700).

Liebe Grüße
Denise

PS: Biggi erreichst Du in einem anderen Forum.